Inloggen
E-mail
Wachtwoord
Paswoord weergeven
Bewaren
Bent u uw wachtwoord vergeten?
Gratis lid worden
Registreer
Registreer
Instellingen
Instellingen
Dynamische koersen 
OFFON
  1. Homepagina
  2. Aandelen
  3. Nederland
  4. Euronext Amsterdam
  5. Galapagos NV
  6. Nieuws
  7. Persberichten
    GLPG   BE0003818359

GALAPAGOS NV

(GLPG)
OverzichtKoersenGrafiekenNieuwsRatingenAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproducten 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiŽle publicatiesSectornieuws
Communiquťs de presse de la sociťtť GALAPAGOS NV
06/10GALAPAGOS : presents new data from the SELECTION Phase 3 program at the United European Ga..
PU
06/10GALAPAGOS : announces completion of patient enrollment for DIVERSITY Phase 3 study with fi..
PU
05/10GALAPAGOS : N.V., - Galapagos presenteert nieuwe data van het SELECTION fase 3-programma o..
PU
04/10GALAPAGOS : Galapagos presenteert nieuwe data van het SELECTION fase 3-programma op het 20..
GL
04/10GALAPAGOS : presents new data from the SELECTION Phase 3 program at the United European Ga..
AQ
04/10GALAPAGOS : N.V., - "Galapagos announces completion of patient enrollment for DIVERSITY Ph..
PU
04/10Galapagos kondigt voltooiing aan van rekrutering voor DIVERSITY fase 3-studie met filgo..
GL
04/10GALAPAGOS : kondigt voltooiing aan van rekrutering voor DIVERSITY fase 3-studie met filgot..
GL
04/10GALAPAGOS : announces completion of patient enrollment for DIVERSITY Phase 3 study with fi..
AQ
21/09GALAPAGOS : increases share capital through subscription right exercises (Form 6-K)
PU
21/09GALAPAGOS : N.V., - Galapagos increases share capital through subscription right exercises
PU
20/09Galapagos verhoogt kapitaal door uitoefening van inschrijvingsrechten
GL
20/09GALAPAGOS : increases share capital through subscription right exercises
AQ
20/09GALAPAGOS : ANNOUNCES POSITIVE CHMP OPINION FOR JYSELECAģ (FILGOTINIB) FOR THE TREATMENT O..
PU
17/09GALAPAGOS : N.v., - galapagos announces positive chmp opinion for jyselecaģ (filgotinib) f..
PU
17/09Galapagos kondigt positieve chmp opinie aan voor jyselecaģ (filgotinib) voor de behande..
GL
17/09GALAPAGOS : Announces positive chmp opinion for jyselecaģ (filgotinib) for the treatment o..
AQ
01/09GALAPAGOS NV : - Bionity - Galapagos announces planned retirement of CEO
AQ
31/08GALAPAGOS : announces planned retirement of CEO (Form 6-K)
PU
30/08Galapagos kondigt gepland pensioen aan van CEO
GL
30/08GALAPAGOS : announces planned retirement of CEO
AQ
05/08Galapagos rapporteert financiële resultaten eerste halfjaar met geheroriënteerde pijpli..
GL
05/08GALAPAGOS : reports H1 financial results with refocused pipeline and operational progress
AQ
15/07GALAPAGOS : N.V., - Galapagos reports positive topline results with selective TYK2 inhibit..
PU
15/07GALAPAGOS : N.V., - Galapagos demonstrates early clinical activity with SIK2/3 inhibition ..
PU
14/07GALAPAGOS : demonstrates early clinical activity with SIK2/3 inhibition in inflammation (F..
PU
14/07GALAPAGOS : reports positive topline results with selective TYK2 inhibitor GLPG3667 in Pha..
PU
14/07Galapagos toont vroege klinische activiteit aan met SIK2/3-remmer bij ontstekingsziekt..
GL
14/07Galapagos meldt positieve resultaten met selectieve TYK2-remmer GLPG3667 in fase 1b-stu..
GL
14/07GALAPAGOS : demonstrates early clinical activity with SIK2/3 inhibition in inflammation
AQ
14/07GALAPAGOS : reports positive topline results with selective TYK2 inhibitor GLPG3667 in Pha..
AQ
10/07Galapagos maakt nieuwe data bekend die een snelle symptoomverbetering en aanhoudende st..
GL
10/07GALAPAGOS : announces new data supporting rapid symptom improvement and sustained steroid-..
AQ
23/06GALAPAGOS : announces departure of CSO Piet Wigerinck later this year (Form 6-K)
PU
22/06Galapagos kondigt vertrek van Chief Scientific Officer Piet Wigerinck aan later dit jaa..
GL
08/06GALAPAGOS : increases share capital through subscription right exercises (Form 6-K)
PU
07/06Galapagos increases share capital through subscription right exercises
GL
04/06GALAPAGOS : SELECTION study on filgotinib in ulcerative colitis published in The Lancet (F..
PU
04/06SELECTION-studie naar filgotinib bij colitis ulcerosa, gepubliceerd in The Lancet
GL
28/05GALAPAGOS : to present data on rheumatoid arthritis at the upcoming European League Agains..
PU
27/05Galapagos presenteert tijdens het congres van de European League Against Rheumatism (EU..
GL
19/05GALAPAGOS : announces first patient enrolled in FILOSOPHY study to advance understanding o..
PU
18/05Galapagos announces first patient enrolled in FILOSOPHY study to advance understanding ..
GL
11/05GALAPAGOS : refocuses pipeline and rightsizes operations (Form 6-K)
PU
06/05Galapagos heroriënteert pijplijn en stroomlijnt organisatie
GL
04/05Transparantieverklaring ontvangen van The Capital Group
GL
04/05GALAPAGOS : Transparency notification received from The Capital Group
AQ
03/05GALAPAGOS : creates new subscription right plans
PU
30/04Galapagos creëert nieuwe inschrijvingsrechtenplannen
GL
28/04GALAPAGOS : Written questions and answers
PU
23/04Gilead Sciences dient goedkeuringsaanvraag in Japan in voor filgotinib voor de behandel..
GL
08/04GALAPAGOS : Extension of lock-up period in Gilead-Galapagos collaboration agreement
AQ
08/04Verlenging van de lock-up-periode in samenwerkingsovereenkomst tussen Gilead & Galapago..
GL
26/03GALAPAGOS NV : - Publication of the annual report and invitation to the ordinary sharehold..
AQ
25/03GALAPAGOS : Statutory auditor's report on the non-consolidated financial statements per 31..
PU
25/03GALAPAGOS : Publication of the annual report and invitation to the ordinary shareholders' ..
AQ
25/03Publicatie van het jaarverslag en uitnodiging voor de gewone algemene vergadering
GL
24/03Galapagos appoints Bart Filius as President and Chief Operating Officer
GL
19/03GALAPAGOS : increases share capital through subscription right exercises
AQ
19/03Galapagos verhoogt kapitaal door uitoefening van inschrijvingsrechten
GL
18/03Oxurion NV Business and Financial Update, FY 2020
AQ
04/03GALAPAGOS NV : - Transparency notification received from The Capital Group
AQ
04/03GALAPAGOS : REPORTS PRIMARY ENDPOINT FOR THE ONGOING FILGOTINIB MANTA AND MANTA-RAy SAFETY..
AQ
04/03Galapagos kondigt primaire eindpunt aan van de lopende MANTA en MANTA-RAy veiligheidss..
GL
03/03Transparency notification received from The Capital Group
GL
19/02GALAPAGOS NV : - Pipeline and capital for growth
AQ
18/02Pipeline and capital for growth
GL
10/02Galapagos and Gilead discontinue ISABELA Phase 3 trials in IPF
GL
10/02GALAPAGOS NV : - The Capital Group holds 10.03% of Galapagos shares
AQ
09/02GALAPAGOS : The Capital Group holds 10.03% of Galapagos shares
AQ
09/02The Capital Group bezit 10,03% van de Galapagos aandelen
GL
22/01GALAPAGOS NV : - NICE recommends Jyseleca on NHS in landmark decision for rheumatoid arthr..
AQ
21/01GALAPAGOS : NICE recommends Jyselecaģ ▼(filgotinib) on NHS in landmark decision for ..
AQ
21/01NICE BEVEELT JYSELECAģ▼ (FILGO : belangrijke beslissing voor behandeling reumatoïde ..
GL
12/01GALAPAGOS NV : - Gilead holds 25.54% of Galapagos shares
AQ
1  2  3  4  5  6  7Volgende
Volgende evenement op GALAPAGOS NV
04/11/21